Provided by Tiger Trade Technology Pte. Ltd.

CALCIMEDICA

0.5880
+0.03165.68%
Post-market: 0.58810.0001+0.02%19:39 EDT
Volume:220.76K
Turnover:125.78K
Market Cap:20.08M
PE:-0.44
High:0.5891
Open:0.5508
Low:0.5469
Close:0.5564
52wk High:7.20
52wk Low:0.4606
Shares:34.14M
Float Shares:19.81M
Volume Ratio:0.52
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3306
EPS(LYR):-1.9700
ROE:-365.70%
ROA:-63.58%
PB:3.64
PE(LYR):-0.30

Loading ...

CalciMedica Price Target Announced at $9.00/Share by Guggenheim

Dow Jones
·
Aug 20

CalciMedica Shareholders Approve 7.5 Million-Share Increase to Equity Incentive Plan

Reuters
·
Aug 20

CalciMedica initiated with a Buy at Guggenheim

TIPRANKS
·
Aug 20

Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and CalciMedica (CALC)

TIPRANKS
·
Aug 13

CalciMedica Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate

Benzinga Earnings
·
Aug 11

CalciMedica Q2 FY26 Net Loss Widens to $7.65 Million

Reuters
·
Aug 11

CalciMedica Q2 Basic EPS USD -0.45

THOMSON REUTERS
·
Aug 11

Press Release: CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Dow Jones
·
Aug 11

CalciMedica Inc Expected to Post a Loss of 28 Cents a Share - Earnings Preview

Reuters
·
Aug 08

CalciMedica announces FDA alignment on Phase 2b Auxora trial design

TIPRANKS
·
Jul 29

CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright

TIPRANKS
·
Jul 29

CalciMedica Reaches FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis

MT Newswires Live
·
Jul 29

CalciMedica - Expects Ind Submission for Cm5480 in Mid-2027

THOMSON REUTERS
·
Jul 29

CalciMedica Announces FDA Alignment on Phase 2B Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

THOMSON REUTERS
·
Jul 29

CalciMedica - Plans Phase 1B Trial for Auxora in Pah with Data Expected Mid-2027

THOMSON REUTERS
·
Jul 29

CalciMedica Inc: Continues to Advance Preparations for Phase 2B Trial

THOMSON REUTERS
·
Jul 29

CalciMedica - FDA Aligns on Phase 2B Primary Endpoint of New-Onset Severe Respiratory Failure

THOMSON REUTERS
·
Jul 29

Calcimedica - Prospectus Covers Resale of up to 56,020,287 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jul 25

Calcimedica Announces Annual Shareholder Meeting

Reuters
·
Jul 14